SC
HZNP

Searle & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Searle & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,350
Closed -$2.47M – 166
2023
Q3 		$2.47M Hold
21,350
– – 0.84% 31
2023
Q2 		$2.14M Sell
21,350
-894
-4% -$94.3K 0.66% 45
2023
Q1 		$2.47M Sell
22,244
-1,106
-5% -$122K 0.81% 37
2022
Q4 		$2.66M Hold
23,350
– – 0.91% 33
2022
Q3 		$1.45M Sell
23,350
-150
-0.6% -$10.5K 0.56% 52
2022
Q2 		$1.87M Buy
23,500
+1,000
+4% +$94.7K 0.74% 44
2022
Q1 		$2.37M Hold
22,500
– – 0.87% 39
2021
Q4 		$2.42M Hold
22,500
– – 0.88% 39
2021
Q3 		$2.46M Hold
22,500
– – 1.01% 36
2021
Q2 		$2.11M Hold
22,500
– – 0.86% 44
2021
Q1 		$2.07M Sell
22,500
-750
-3% -$63.3K 0.92% 40
2020
Q4 		$1.7M Buy
23,250
+10,500
+82% +$780K 0.82% 47
2020
Q3 		$990K Hold
12,750
– – 0.54% 54
2020
Q2 		$709K Hold
12,750
– – 0.41% 68
2020
Q1 		$378K Buy
+12,750
New +$431K 0.27% 79
2017
Q3 		– Sell
-10,000
Closed -$119K – 132
2017
Q2 		$119K Hold
10,000
– – 0.08% 124
2017
Q1 		$781K Buy
+10,000
New +$162K 0.55% 56

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Searle & Co's HZNP Position: Q4 2023 in Review

Searle & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 21,350 shares — an estimated $2.47M sold.

Searle & Co first reported a position in HZNP in Q1 2017 and held it in 17 quarters. The position peaked at $2.66M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Searle & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Searle & Co sold 21,350 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.47M.
  • Searle & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 17 quarters.
  • Searle & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.66M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Searle & Co's 13F filing for Q4 2023, filed 6 Feb 2024.